

**NSGO publications: (May 2007)**

**Peer reviewed articles:**

Sundfor K, Trope CG, Hogberg T, Onsrud M, Koern J, Simonsen E, Bertelsen K, Westberg R.

Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A  
Cancer. 1996 Jun 1;77(11):2371-8.

Tropé C., Kaern J., Hogberg T., Abeler V., Hagen B., Kristensen G., Onsrud M., Pettersen E., Rosenberg P., Sandvei R., Sunfor K. And Vergote I.  
Randomized study on adjuvant chemotherapy in stage I high risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument  
Annals of Oncology 11, 281-288, 2000

Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope , Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S.  
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.  
J Natl Cancer Inst. 2000 May 3;92(9):699-708.

Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelde P, Gore E, Kaern J, Verrelst H, Sjøvall K, Timmerman D, Vandewalle J, Van Gramberen , Trope CG.  
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.  
Lancet. 2001 Jan 20;357(9251):176-82.

The International Collaborative Ovarian Neoplasms (ICON) Group.  
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON3 randomised trial.  
Lancet 360:505-515, 2002

Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J,

Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W  
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.  
Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:144-8.

Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Baekelandt M, Lopez AB, Hirte H, Aavall-Lundqvist E, Lorenz E, Cerar O  
First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival.  
Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:221.

Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart J, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E.  
Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.  
J Clin Oncol. 2006 Jan 1;24(1):45-51

#### **Consensus statements/reviews:**

Allen DG, Baak J, Belpomme D, Berek JS, Bertelsen K, ten Bokkel Huinink W, van der Burg ME, Calvert AH, Conte PF, Dauplat J, et al  
Advanced epithelial ovarian cancer: 1993 consensus statements.  
Ann Oncol. 1993;4 Suppl 4:83-8.

Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore , Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck J, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Willemse PH, et al  
Advanced epithelial ovarian cancer: 1998 consensus statements.  
Ann Oncol. 1999;10 Suppl 1:87-92

Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore , Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck J, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Thigpen JT, Trope C, Tuxen K, Vergote I, Vermorken JB, Willemse PH.  
Epithelial ovarian cancer (advanced stage): consensus conference (1998)  
Gynecol Obstet Fertil. 2000 Jul-Aug;28(7-8):576-83.

Piccart MJ, Stuart GC, Cassidy J, Bertelsen K, Parmar MK, Eisenhauer EA, Kaye B, Trope C, Swenerton K, Harper P, Vermorken JB.  
Intergroup collaboration in ovarian cancer: a giant step forward.  
Ann Oncol. 1999;10 Suppl 1:83-6.

Vergote I, Rustin GJS, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MKB, Friedlander M, Jakobsen, A, Vermorken JB,  
New Guidelines to Evaluate the Response to Treatment in Solid Tumors  
J Natl C Inst 92: 1534-1535, 2000

du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U  
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).  
Ann Oncol. 2005 Oct;16(suppl\_8):viii7-viii12.

Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Quinn M, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Trimble E, Thigpen T, Vasey P, Vergote I, Verheijen R, Vermorken J, Wagner U.  
3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration.  
Ann Oncol. 2005 Oct;16 Suppl 8:viii36-viii3

Thigpen T, Stuart G, du Bois A, Friedlander M, Fujiwara K, Guastalla JP, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Poveda A, Provencher D, Stehman F, Vergote I.  
Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens.  
Ann Oncol. 2005 Oct;16 Suppl 8:viii13-viii19

## **Published abstracts:**

Kristensen G, Vergote IV, Stuart G, Izquierdo Delso M, Mirza M, Aaval- Lundquist E, Lopez AB, Ridderheim M, Havsteen H, Scheistroen M, Eisenhauer E.  
First line treatment of ovarian cancer FIGO stage Ib-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-GCCG-NCIC CTG Gynecological Cancer Intergroup phase III trial.  
Proc Am Soc Clin Oncol abst # 805. 2002.

Vergote I, Kristensen G, Stuart G, Aaval-Lundquist E, Kaern J, Eisenhauer E.  
First line treatment of ovarian cancer FIGO stage Ib-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-GCCG-NCIC CTG Gynecological Cancer Intergroup phase III trial.  
Int J Gynecol Cancer. 12(5): 521 (abstract # OV007), 2002

Kristensen GB et al.  
First Line Treatment of Ovarian Cancer: Paclitaxel/Epirubicin/Carboplatin (TEC) versus Paclitaxel/Carboplatin (TC). Report on progression free survival  
Proc Am Soc Clin Oncol abst # 5003. 2004.

I. Vergote, G. Kristensen, G. Stuart, J.M. del Campo J. Kærn, M. Baekelandt, A.B Lopez, H. Hirte, E. Aavall-Lundquist, E. Lorenz, O. Cerar  
First line treatment of ovarian/tubal/peritoneal cancer figo stage Iib-IV with paclitaxel/ carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC-GCG, and NCIC-GCG. Results on progression free survival.  
International Journal of Gynecological Cancer Suppl 1, 2004. Abst#007

Britta Nordström, Tuula Salmi, Mansoor R Mirza, Vera Abeler and Gunnar Kristensen  
Exemestane in advanced and recurrent endometrial carcinoma. A phase II study.  
J Clin Oncol 2006;24,18S:266, abstract #5042

## **Communications:**

Kristensen G, Vergote IV, Stuart G, Izquierdo Delso M, Mirza M, Aaval- Lundquist E, Lopez AB, Ridderheim M, Havsteen H, Scheistroen M, Eisenhauer E.  
First line treatment of ovarian cancer FIGO stage Ib-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-GCCG-NCIC CTG Gynecological Cancer Intergroup phase III trial.  
Am Soc Clin Oncol 2002

Stuart G, Kristensen G, Vergote IV, Izquierdo Delso M, Mirza M, Aaval-Lundquist E, Lopez AB, Ridderheim M, Havsteen H, Scheistroen M, Eisenhauer E.  
First line treatment of ovarian cancer FIGO stage Ib-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-GCCG-NCIC CTG Gynecological Cancer Intergroup phase III trial.

13th International Meeting of The European Society of Gynecologic Oncology  
Brussels, April 2003

Kristensen GB

First Line Treatment of Ovarian Cancer FIGO stages IIb-IV with  
Paclitaxel/Epirubicin/Carboplatin (TEC) vs Paclitaxel/Carboplatin (TC).  
Interim results of a GCIG Intergroup Phase III Trial .  
ESMO Educational symposium. Valencia, Febr 2003

Kristensen GB et al.

First Line Treatment of Ovarian Cancer: Paclitaxel/Epirubicin/Carboplatin (TEC) versus  
Paclitaxel/Carboplatin (TC). Report on progression free survival  
40<sup>th</sup> Annual Meeting American Society of Clinical Oncology (ASCO) New Orleans June  
2004.

I. Vergote, G. Kristensen, G. Stuart, J.M. del Campo J. Kærn, M. Baekelandt, A.B Lopez, H.  
Hirte, E. Aavall-Lundquist, E. Lorenz, O. Cerar

First line treatment of ovarian/tubal/peritoneal cancer figo stage IIb-IV with paclitaxel/  
carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study  
of the NSGO, EORTC-GCG, and NCIC-GCG. Results on progression free survival.  
10<sup>th</sup> Biennial International Gynecologic Cancer Society Meeting, Edinburgh, October 2004

Kristensen GB

First Line Treatment of Ovarian Cancer FIGO stages IIb-IV with  
Paclitaxel/Epirubicin/Carboplatin (TEC) vs Paclitaxel/Carboplatin (TC).  
A GCIG Intergroup Phase III Trial . Report on progression free survival.  
ESMO Educational symposium. Valencia, Febr 2005

Herrstedt J, Plaza J, Schmalfeldt B, Mueller H-H, Kristensen G, Berton-Rigaud D, Belau A,  
Loibl S, Wollschlaeger K, du Bois A for the GCIG Intergroup of NSGO (Scandinavia),  
GINECO (France) and AGO-OVAR (Germany)

Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line  
treatment in women with ovarian cancer: A randomized phase III GCIG Intergroup study  
(AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)  
ECCO, Paris, November 2005